-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to data from Meinenet, in the first quarter of 2021, the sales of chemical drugs in public hospitals in key cities rose by 21.
Three domestic pharmaceutical companies, Qilu and Yangzijiang, "breakthrough" in sales of anti-tumor and immunomodulators
Three domestic pharmaceutical companies, Qilu and Yangzijiang, "breakthrough" in sales of anti-tumor and immunomodulators2020-2021Q1 quarterly sales of chemical drugs in public hospitals in key cities (unit: 100 million yuan)
Source: Competitive pattern of chemical drug terminal in public hospitals in key cities
According to data from Mi Nei.
2021Q1 chemical drug city pattern of public hospitals in some key cities (unit: 100 million yuan)
Source: Competitive pattern of chemical drug terminal in public hospitals in key cities
From the perspective of the urban structure, Beijing, Shanghai and Guangzhou are still among the best, with sales exceeding 4 billion yuan
The TOP10 ranking has changed! Three major products soared by over 50%, Qilu "counter-attacked" Roche
The TOP10 ranking has changed! Three major products soared by over 50%, Qilu "counter-attacked" RocheTop 10 chemical products in public hospitals in key cities
Source: Competitive pattern of chemical drug terminal in public hospitals in key cities
Among the TOP10 products, there are the most anti-tumor and immunomodulators, with 4, the systemic anti-infective drugs and the blood and hematopoietic system drugs each have two
Top 10 Chemical Drug Brands in Public Hospitals in Key Cities
Source: Competitive pattern of chemical drug terminal in public hospitals in key cities
Among the TOP10 brands, Yangtze River’s Dezocine injection has been ranked first for many years; from the perspective of sales growth, only Roche’s bevacizumab injection has a negative growth, and all nine brands have a positive growth
Quarterly sales of bevacizumab injection in public hospitals of key cities in Q1 2020-2021 (unit: 100 million yuan)
Source: Competitive pattern of chemical drug terminal in public hospitals in key cities
Bevacizumab is one of Roche's "troika"
Quarterly sales of iodixanol injection in public hospitals in key cities in Q1 2020-2021 (unit: 100 million yuan)
Source: Competitive pattern of chemical drug terminal in public hospitals in key cities
Iodixanol is an X-ray non-ionic iodine contrast agent, and it is currently the largest contrast agent product in the domestic market
